Profil
- Ausbildung von Studierenden der Humanmedizin, Zahnmedizin, Pharmazie, biomedizinischen Wissenschaften sowie von PhD-Studierenden an der Graduate School of Cellular and Biomedical Sciences (GCB) der Universität Bern
- 10 Forschungsgruppen; Forschungsschwerpunkte: Erforschung epidemiologischer und pathophysiologischer Prozesse sowie Diagnose, Prognose und Therapieansätze von Blutkrankheiten, pathophysiologische Prozesse, die zu Entzündungen und Tumorerkrankungen beitragen
- Clinical Study Management Unit (21 Studien und 2 Register im 2025 durchgeführt)/ Biobanking
- Grösstes klinisches Zelltherapieprogramm der Schweiz
Externe Partner
Vorstand und Beirat des Hereditären TTP Registers (www.ttpregistry.net); University of Oklahoma Health Sciences Center, Norman, OK, USA; American Society for Transplantation and Cellular Therapy – Survivorship Special Interest Group, EBMT Chronic Malignancies Working Party (CMWP); DKFZ Heidelberg, Deutschland; Hämatologie, Universitätsspital Basel, Schweiz; MRC Cambridge Stem Cell Institute, University of Cambridge, UK; Universitätsspital Zürich und ETH Zürich, Schweiz; Swiss MDS Registry and Biobank; University of Ottawa, Ottawa, Kanada; Lowy Cancer Research Centre, UNSW Sidney, NSW, Australien; Stiftung MPN Forschung Schweiz (Mitgründer); Schweizer Kompetenznetzwerk für Mastozytose (Mitgründer); Memorial Sloan Kettering Cancer Center, New York, USA; NYU Langone Perlmutter Cancer Center, New York, USA; Ajax Therapeutics, Cambridge, MA, USA; Landmark BioVentures; Nandasi Pharma Advisors; BleednFire Therapeutics (spin-off UNIBE, co-founders); Silence Therapeutics Silence Therapeutics GmbH, Berlin, Deutschland & plc, London, UK; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA; Synapse Research Institute, Maastricht, Niederlande; Synapse Research Institute, Maastricht, Niederlande; Division of Angiology and Hemostasis, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Schweiz; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA; Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, UK; Australian Centre for Blood Diseases, Monash University, Melbourne, Australien; University Medical Centre Hamburg-Eppendorf, Hamburg, Deutschland; Baylor College of Medicine, Texas, USA; CSL Behring; MD Anderson Cancer Center, Houston, Texas, USA; Albert Einstein College of Medicine, Bronx, NY, USA; University of Texas at Austin, Austin, Texas, USA; Institute of Hematology and Transfuson Medicine, Warschau, Polen; Max Planck Institute for Plant Breeding Research; Department of Internal Medicine, Cardiology Services, Sanford University of South Dakota Medical Cente, USAr; Institute of Biochemistry of the Romanian Academy , Bukarest, Rumänien
Grants
- SNF Projektförderung 219306, 10000274, 10003602, 10005120, 10006706, 10006789; SNSF Scientific Exchanges 238259
- Innosuisse 114.430 IP-LS, Innobooster, Innogrant, Unitectra PoC, Venture kick
- Nationales Forschung Zentrum, Polen, Grant 2021/43/B/NZ5/03345
- SPHN Demonstrator project Therapy-related myeloid neoplasms after cytotoxic treatment (consortium member); Helmut Horton Stiftung Consortium Project for Clinical Translation 2024-CON-027 Safety and Efficacy of Intravenous Thrombolysis in Stroke Patients on Recent DOAC Therapy: DO-IT Switzerland Trial (co-applicant); Canadian Institutes of Health Research project grant 527424 Development of a risk stratification score for recurrent venous thromboembolism and clinicallyrelevant bleeding in patients with cancerassociated venous thromboembolism. CANCATCH Study (co-applicants)
- Berner Krebsliga, Jacques und Gloria Gossweiler Stiftung, Fondazione San Salvatore, Stiftung für krebskranke Kinder (Basel); Foundation for the Fight against Cancer, Swiss Hemophilia Network
